Vandortuzumab, the novel protein, shows a intriguing therapeutic substance targeting CD40, a key target involved in body's response. Its mechanism of action involves inhibiting CD40 pathway, seemingly leading to lower https://www.targetmol.com/compound/vandortuzumab